Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04232995
Other study ID # RTazeem
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 12, 2019
Est. completion date November 1, 2020

Study information

Verified date August 2021
Source Dow University of Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the efficacy of balance training in Diabetic Neuropathy. Control group will receive general exercises while Eperimental/ Interventional group will receive Balance exercises along with general exercises.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date November 1, 2020
Est. primary completion date September 1, 2020
Accepts healthy volunteers No
Gender All
Age group 30 Years to 60 Years
Eligibility Inclusion Criteria: - Age group: 30-60 years - Diabetes type II patients diagnosed with peripheral neuropathy by medical doctor for at least 5 years - Neuropathy present (on the basis of Michigan Neuropathy Screening Instrument - Have balance impairment ( evaluation on Berg Balance Scale) Exclusion Criteria: - Neuropathy due to other medical conditions like Vitamin deficiency, Hypothyroidism, Auto-immune/ demyelinating diseases - Foot ulcers - Lower limb amputee - Vestibular diseases - Retinopathy - Cardiac problems - Hemiplegia/ Stroke

Study Design


Related Conditions & MeSH terms

  • Diabetic Neuropathies
  • Diabetic Neuropathy With Neurologic Complication
  • Peripheral Nervous System Diseases

Intervention

Other:
Balance Training
Balance enhancing exercises
General Exercises
General Exercises

Locations

Country Name City State
Pakistan Institute of Physical Medicine and Rehabilitation, Dow University of Health Sciences Karachi Sindh

Sponsors (1)

Lead Sponsor Collaborator
Dow University of Health Sciences

Country where clinical trial is conducted

Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Berg Balance Scale The Berg Balance Scale (BBS) is a 56-point scale that evaluates 14 tasks. Katherine Berg developed this test to assess the level of function and balance in various patient populations. Minimum score is 0 (means severe balance deficit) and Maximum score is 56 (means No balance deficit) Baseline (Pre treatment)
Primary Berg Balance Scale The Berg Balance Scale (BBS) is a 56-point scale that evaluates 14 tasks. Katherine Berg developed this test to assess the level of function and balance in various patient populations. Minimum score is 0 (means severe balance deficit) and Maximum score is 56 (means No balance deficit) At 4th week of treatment
Primary Berg Balance Scale The Berg Balance Scale (BBS) is a 56-point scale that evaluates 14 tasks. Katherine Berg developed this test to assess the level of function and balance in various patient populations. Minimum score is 0 (means severe balance deficit) and Maximum score is 56 (means No balance deficit) At 8th week of treatment (Post treatment )
See also
  Status Clinical Trial Phase
Recruiting NCT03426085 - The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes Phase 2